(Q34460803)

2 August 2017

0 references

1 reference

title

Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials (English)

1 reference

2 August 2017

0 references

1 reference

4

Arnold S Monto

1 reference

2 August 2017

Joanna Dobson

1

1 reference

2 August 2017

Richard J Whitley

series ordinal

2

1 reference

2 August 2017

Stuart Pocock

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

30 January 2015

1 reference

2 August 2017

1 reference

2 August 2017

volume

385

1 reference

2 August 2017

issue

9979

1 reference

2 August 2017

page(s)

1729-1737

1 reference

Rational design of potent sialidase-based inhibitors of influenza virus replication

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Structure of the catalytic and antigenic sites in influenza virus neuraminidase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Perspectives on antiviral use during pandemic influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

The threat of an avian influenza pandemic.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Confidence intervals for the number needed to treat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Oral oseltamivir treatment of influenza in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Oseltamivir effect on antibiotic-treated lower respiratory tract complications in virologically positive randomized trial participants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962449-1

7 January 2021

10.1016/S0140-6736(14)62449-1

Identifiers

DOI

1 reference

2 August 2017

1 reference